Full Press Release Details
Accessibility: Skip TopNav
Summit to Present at Wedbush Securities Life Science Conference
August 06, 2013 07:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
SUMMIT TO PRESENT AT WEDBUSH SECURITIES LIFE SCIENCES CONFERENCE IN THE US
Oxford, UK, 6 August 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection ('CDI'), announces that it will be presenting at the Wedbush Securities Life Sciences Management Access Conference in New York on Wednesday 14 August at 08:35 EST (13:35 BST).
Mr Glyn Edwards, the Company's Chief Executive Officer, will provide a corporate overview highlighting its lead molecules SMT C1100 for the treatment of DMD and SMT 19969 for the treatment of CDI. In addition, he will participate in the 'Leaders in DMD and Rare Diseases' panel discussion to be held on Tuesday 13 August at 11:30 EST.
A copy of the presentation will be available immediately after the event from the Investors Relations section of the Company's website at www.summitplc.com .
Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 939 |
| Nomura Code Securities (Nominated Adviser and Joint broker) Chris Collins / Jonathan Senior / Giles Balleny | Tel: +44 (0)20 7776 1200 |
| Hybridan LLP (Joint broker) Claire Louise Noyce / Deepak Reddy | Tel: +44 (0)207 947 4350 |
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
| MacDougall Biomedical Communications (US media contact) Michelle Avery | Tel: +1 781-235-3060 |